We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences
Read MoreHide Full Article
QIAGEN N.V. (QGEN - Free Report) recently announced a collaboration with Penn State University, United States, to create a shared research and education facility for fast-developing microbiome sciences. The company will provide instruments and kits for preparing and processing microbial samples for the flagship project at Penn State’s Huck Institutes of the Life Sciences, “One Health Microbiome Center”, to support faculty and students.
The latest development will significantly boost the company’s Life Sciences business area.
Significance of the Collaboration
Microbiome research aims to explore the relationships between microorganisms such as bacteria, fungi and viruses and their hosts. It can help better understand the microbiome’s impact on health, diseases and ecological processes to develop novel diagnostic solutions and therapeutic strategies.
Image Source: Zacks Investment Research
One of the leading academic research institutions in the field of microbiome research, Penn State is among the top 30 public research universities in the United States, with more than $1.2 billion in annual research expenditures. The first-in-kind partnership is anchored by a shared vision for an interconnection between the health of humans, animals and ecosystems, which will help shape research, education and outreach in the nascent field of the microbiome sciences and potentially accelerate the careers of a new generation of aspiring scientists.
News in Detail
The university-industry partnership will investigate research opportunities that address challenges and research gaps facing the microbiome, which involves research into a community of microorganisms that can be found living together in any given environment, including the human body. In doing so, this new partnership will provide QIAGEN with a site to support the development of the new microbiome solutions.
The facility will also provide vital industry research and training opportunities for next-generation scientists. This includes an internship program for Penn State graduate students at QIAGEN laboratories at the European operational headquarters in Hilden, Germany, helping them prepare for careers in the biotechnology industry. According to the head of QIAGEN’s Life Sciences business, it will also foster relationships with the microbiome research community, enabling to better develop new products for microbiome research based on direct customer feedback.
Among the multiple projects involved in the collaboration, the team will support the worldwide science education program “Discover the Microbes Within! The Wolbachia Project”. This program enables students at the middle and high school levels, as well as those in college, to learn about arthropods and collect scientific data about the bacterial endosymbiont Wolbachia pipientis. This bacterium is often used as a model organism to investigate animal-microbe interactions, genetics, evolution, ecology and human health.
Other Developments in the Life Sciences Business
Earlier in November 2023, QIAGEN expanded its sample technologies portfolio with the introduction of two new products aimed at supporting researchers in managing diverse materials such as bone, tissue and soil samples. The TissueLyser III complements the company’s portfolio of high-throughput instruments, which include QIAcube HT, QIAxcel Connect and QIAsymphony. The new RNeasy PowerMax Soil Pro Kit is specifically designed for challenging soil samples, particularly those rich in PCR inhibitors such as compost, sediment and manure.
The company also launched three new QIAcuity kits to enhance digital PCR applications in biopharma research and food safety, ensuring precise quantification, increased sensitivity and cost efficiency. The QIAcuity Software 2.5 update will help streamline digital PCR analysis with precise run temperature and sample dilution information critical to biotech and pharma reporting and auditing.
Industry Prospects
Per a Research report, the global microbiome sequencing services market was valued at $1.37 billion in 2022 and is expected to witness a CAGR of 10.9% till 2030.
Price Performance
In the past six months, QGEN shares have dropped 9.8% against the industry’s 2.4% rise.
Haemonetics’ stock has risen 13.3% in the past year. Earnings estimates for Haemonetics have remained constant at $3.89 in fiscal 2024 and increased from $4.15 to $4.18 in fiscal 2025 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have remained constant at $1.97 in the past 30 days. Shares of the company have decreased 30.9% in the past year compared with the industry’s decline of 1.2%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%.
Estimates for DaVita’s 2023 earnings per share have remained constant at $8.07 in the past 30 days. Shares of the company have risen 7.4% in the past year compared with the industry’s growth of 2.9%.
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 36.6%. In the last reported quarter, it delivered an average earnings surprise of 48.4%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences
QIAGEN N.V. (QGEN - Free Report) recently announced a collaboration with Penn State University, United States, to create a shared research and education facility for fast-developing microbiome sciences. The company will provide instruments and kits for preparing and processing microbial samples for the flagship project at Penn State’s Huck Institutes of the Life Sciences, “One Health Microbiome Center”, to support faculty and students.
The latest development will significantly boost the company’s Life Sciences business area.
Significance of the Collaboration
Microbiome research aims to explore the relationships between microorganisms such as bacteria, fungi and viruses and their hosts. It can help better understand the microbiome’s impact on health, diseases and ecological processes to develop novel diagnostic solutions and therapeutic strategies.
Image Source: Zacks Investment Research
One of the leading academic research institutions in the field of microbiome research, Penn State is among the top 30 public research universities in the United States, with more than $1.2 billion in annual research expenditures. The first-in-kind partnership is anchored by a shared vision for an interconnection between the health of humans, animals and ecosystems, which will help shape research, education and outreach in the nascent field of the microbiome sciences and potentially accelerate the careers of a new generation of aspiring scientists.
News in Detail
The university-industry partnership will investigate research opportunities that address challenges and research gaps facing the microbiome, which involves research into a community of microorganisms that can be found living together in any given environment, including the human body. In doing so, this new partnership will provide QIAGEN with a site to support the development of the new microbiome solutions.
The facility will also provide vital industry research and training opportunities for next-generation scientists. This includes an internship program for Penn State graduate students at QIAGEN laboratories at the European operational headquarters in Hilden, Germany, helping them prepare for careers in the biotechnology industry. According to the head of QIAGEN’s Life Sciences business, it will also foster relationships with the microbiome research community, enabling to better develop new products for microbiome research based on direct customer feedback.
Among the multiple projects involved in the collaboration, the team will support the worldwide science education program “Discover the Microbes Within! The Wolbachia Project”. This program enables students at the middle and high school levels, as well as those in college, to learn about arthropods and collect scientific data about the bacterial endosymbiont Wolbachia pipientis. This bacterium is often used as a model organism to investigate animal-microbe interactions, genetics, evolution, ecology and human health.
Other Developments in the Life Sciences Business
Earlier in November 2023, QIAGEN expanded its sample technologies portfolio with the introduction of two new products aimed at supporting researchers in managing diverse materials such as bone, tissue and soil samples. The TissueLyser III complements the company’s portfolio of high-throughput instruments, which include QIAcube HT, QIAxcel Connect and QIAsymphony. The new RNeasy PowerMax Soil Pro Kit is specifically designed for challenging soil samples, particularly those rich in PCR inhibitors such as compost, sediment and manure.
The company also launched three new QIAcuity kits to enhance digital PCR applications in biopharma research and food safety, ensuring precise quantification, increased sensitivity and cost efficiency. The QIAcuity Software 2.5 update will help streamline digital PCR analysis with precise run temperature and sample dilution information critical to biotech and pharma reporting and auditing.
Industry Prospects
Per a Research report, the global microbiome sequencing services market was valued at $1.37 billion in 2022 and is expected to witness a CAGR of 10.9% till 2030.
Price Performance
In the past six months, QGEN shares have dropped 9.8% against the industry’s 2.4% rise.
Zacks Rank and Key Picks
QIAGEN currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Insulet (PODD - Free Report) and DaVita (DVA - Free Report) . Haemonetics carries a Zacks Rank #2 (Buy), while Insulet and DaVita each sport a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has risen 13.3% in the past year. Earnings estimates for Haemonetics have remained constant at $3.89 in fiscal 2024 and increased from $4.15 to $4.18 in fiscal 2025 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have remained constant at $1.97 in the past 30 days. Shares of the company have decreased 30.9% in the past year compared with the industry’s decline of 1.2%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.5%.
Estimates for DaVita’s 2023 earnings per share have remained constant at $8.07 in the past 30 days. Shares of the company have risen 7.4% in the past year compared with the industry’s growth of 2.9%.
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 36.6%. In the last reported quarter, it delivered an average earnings surprise of 48.4%.